Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.44 |
| ▸ | PRKCA | P17252 | 4/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | STK10 | O94804 | 3/20 | 0.41 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340785 | 0.79 | GSK3B (0.47) | GSK3BPRKCASTK10SLKTMEM97 | |
| SCHEMBL2340281 | 0.77 | GSK3B (0.43) | GSK3BPRKCASTK10SLK | |
| SCHEMBL1395700 | 0.77 | GSK3B (0.58) | GSK3BPRKCA | |
| SCHEMBL2345991 | 0.75 | DDB1 (0.42) | WDR5ALOX5MAP3K5 | |
| SCHEMBL13241018 | 0.75 | DDB1 (0.42) | WDR5ALOX5MAP3K5 | |
| SCHEMBL2349161 | 0.74 | PRKCA (0.51) | GSK3BPRKCASLK | |
| SCHEMBL5367096 | 0.73 | DRD1 (0.41) | WDR5 | |
| SCHEMBL4789169 | 0.70 | GSK3B (0.62) | GSK3BPRKCASTK10SLK | |
| SCHEMBL2349685 | 0.70 | KDR (0.51) | GSK3BPRKCA | |
| SCHEMBL3669622 | 0.67 | GSK3B (0.60) | GSK3BPRKCASTK10SLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2173748-B1 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2173748-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | MKI67, POLI, DHPS | GSK3B 1887/4885PRKCA 881/4885WDR5 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.